Inventiva joins the Euronext Tech Leaders segment
- Inventiva has been selected for inclusion in Euronext’s new
segment alongside more than 100 high-growth and Tech-driven
European companies
- International investors will be able to track the Euronext Tech
Leaders segment through a new index
Daix (France), Long
Island City (New York, United States), June 7, 2022 –
Inventiva (Euronext Paris and Nasdaq: IVA) (the
“Company”), a clinical-stage biopharmaceutical
company focused on the development of oral small molecule therapies
for the treatment of patients with non-alcoholic steatohepatitis
(NASH) and other diseases with significant unmet medical needs,
today announced that it will join the Euronext Tech Leaders
initiative, a new Euronext segment comprised of more than 100
high-growth and leading Tech companies across Europe.
Frédéric Cren, Chairman, Chief Executive
Officer and cofounder of Inventiva, stated: “We are proud
to join other Tech Leaders in this new segment. This is a
recognition of our successes and our global potential as a
tech-driven biopharmaceutical company, and we are confident that
being part of this international initiative will bring further
exposure to Inventiva. This is a great tribute to the work and
dedication of all Inventiva employees.”
To be included, companies must meet a specific
set of financial criteria, including a market capitalization of €
300 million and minimum growth rate conditions. This segment aims
to be a catalyst for the next generation of Tech Leaders, which
stand to benefit from Euronext’s strong visibility and global
investor base. Investors will be able to track Euronext Tech
Leaders with a new, dedicated index that becomes available in
July.
About Euronext
Euronext is the leading pan-European market
infrastructure, connecting European economies to global capital
markets, to accelerate innovation and sustainable growth. It
operates regulated exchanges in Belgium, France, Ireland, Italy,
the Netherlands, Norway and Portugal. With close to 2,000 listed
issuers and around €6.6 trillion in market capitalisation as of end
March 2022, it has an unmatched blue-chip franchise and a strong
diverse domestic and international client base. Euronext operates
regulated and transparent equity and derivatives markets, one of
Europe’s leading electronic fixed income trading markets and is the
largest centre for debt and funds listings in the world. Its total
product offering includes Equities, FX, Exchange Traded Funds,
Warrants & Certificates, Bonds, Derivatives, Commodities and
Indices. The Group provides a multi-asset clearing house through
Euronext Clearing, and custody and settlement services through
Euronext Securities central securities depositories in Denmark,
Italy, Norway and Portugal. Euronext also leverages its expertise
in running markets by providing technology and managed services to
third parties. In addition to its main regulated market, it also
operates a number of junior markets, simplifying access to listing
for SMEs. For the latest news, go to euronext.com or follow us on
Twitter (twitter.com/euronext) and LinkedIn
(linkedin.com/euronext).
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the research and development of oral small
molecule therapies for the treatment of patients with NASH and
other diseases with significant unmet medical needs. The Company
benefits from a strong expertise and experience in the domain of
compounds targeting nuclear receptors, transcription factors and
epigenetic modulation. Inventiva’s lead product candidate,
lanifibranor, is currently in a pivotal Phase III clinical trial,
NATiV3, for the treatment of adult patients with NASH, a common and
progressive chronic liver disease for which there are currently no
approved therapies.
The Company has established a strategic
collaboration with AbbVie in the area of autoimmune diseases that
resulted in the discovery of the drug candidate cedirogant
(ABBV-157), an oral RORg inverse agonist which is being evaluated
in a Phase IIb clinical trial, led by AbbVie, in adult patients
with moderate to severe chronic plaque psoriasis. Inventiva’s
pipeline also includes odiparcil, a drug candidate for the
treatment of adult mucopolysaccharidoses (MPS) VI patients. As part
of Inventiva’s decision to focus clinical efforts on the
development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with
respect to its potential further development. Inventiva is in the
process of selecting an oncology development candidate for its
Hippo signalling pathway program.
The Company has a scientific team of
approximately 80 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, and clinical development. It owns an extensive
library of approximately 240,000 pharmacologically relevant
molecules, approximately 60% of which are proprietary, as well as a
wholly‑owned research and development facility.
Inventiva is a public company listed on
compartment C of the regulated market of Euronext Paris (ticker:
IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com.
Contacts
InventivaPascaline ClercVP of Global External
Affairsmedia@inventivapharma.com+1 240 620 9175 |
Brunswick GroupLaurence Frost / Tristan Roquet
Montegon / Aude LepreuxMedia
relationsinventiva@brunswickgroup.com+33 1 53 96 83 83 |
Westwicke, an ICR CompanyPatricia L. BankInvestor
relationspatti.bank@westwicke.com+1 415 513 1284 |
|
|
|
Important Notice
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release are forward-looking statements. These statements include,
but are not limited to, forecasts and estimates with respect to
Inventiva’s pre-clinical programs and clinical trials, clinical
trial data releases, including for part 1 of the Phase III clinical
trial of lanifibranor in patients with NASH, pipeline and
preclinical and clinical development plans, reaching anticipated
milestones and conditions precedent for Tranche A and/or Tranche B,
potential future financings and strategic transactions, milestone
payments, royalties and product sales, future activities,
expectations, plans, growth and prospects of Inventiva and the
sufficiency of Inventiva’s cash resources and cash runway. Certain
of these statements, forecasts and estimates can be recognized by
the use of words such as, without limitation, “believes”,
“anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”,
“may”, “will”, “would”, “could”, “might”, “should”, and “continue”
and similar expressions. Such statements are not historical facts
but rather are statements of future expectations and other
forward-looking statements that are based on management's beliefs.
These statements reflect such views and assumptions prevailing as
of the date of the statements and involve known and unknown risks
and uncertainties that could cause future results, performance or
future events to differ materially from those expressed or implied
in such statements. Future events are difficult to predict and may
depend upon factors that are beyond Inventiva's control. There can
be no guarantees with respect to pipeline product candidates that
the clinical trial results will be available on their anticipated
timeline, that future clinical trials will be initiated as
anticipated, that product candidates will receive the necessary
regulatory approvals, or that any of the anticipated milestones by
Inventiva or its partners will be reached or that conditions
precedent to receive funds under the credit facility will be met on
their expected timeline, or at all. Actual results may turn out to
be materially different from the anticipated future results,
performance or achievements expressed or implied by such
statements, forecasts and estimates, due to a number of factors,
including that Inventiva is a clinical-stage company with no
approved products and no historical product revenues, Inventiva has
incurred significant losses since inception, Inventiva has a
limited operating history and has never generated any revenue from
product sales, Inventiva will require additional capital to finance
its operations, Inventiva's future success is dependent on the
successful clinical development, regulatory approval and subsequent
commercialization of current and any future product candidates,
preclinical studies or earlier clinical trials are not necessarily
predictive of future results and the results of Inventiva's
clinical trials may not support Inventiva's product candidate
claims, Inventiva may encounter substantial delays in its clinical
trials or Inventiva may fail to demonstrate safety and efficacy to
the satisfaction of applicable regulatory authorities, enrolment
and retention of patients in clinical trials is an expensive and
time-consuming process and could be made more difficult or rendered
impossible by multiple factors outside Inventiva's control,
Inventiva's product candidates may cause adverse drug reactions or
have other properties that could delay or prevent their regulatory
approval, or limit their commercial potential, Inventiva faces
substantial competition and Inventiva’s business, and preclinical
studies and clinical development programs and timelines, its
financial condition and results of operations could be materially
and adversely affected by the current COVID-19 pandemic and
geopolitical events, such as the conflict between Russia and
Ukraine, which could delay the initiation, enrolment and completion
of Inventiva’s clinical trials on anticipated timelines or at all.
Given these risks and uncertainties, no representations are made as
to the accuracy or fairness of such forward-looking statements,
forecasts and estimates. Furthermore, forward-looking statements,
forecasts and estimates only speak as of the date of this press
release. Readers are cautioned not to place undue reliance on any
of these forward-looking statements.
Please refer to the Universal Registration
Document for the year ended December 31, 2021 filed with the
Autorité des Marchés Financiers on March 11, 2022 and the Annual
Report on Form 20-F for the year ended December 31, 2021 filed with
the Securities and Exchange Commission on March 11, 2022 for
additional information in relation to such factors, risks and
uncertainties.
All information in this press release is as of
the date of the release. Except as required by law, Inventiva has
no intention and is under no obligation to update or review the
forward-looking statements referred to above.
- Inventiva - PR - Inventiva joins the Euronext Tech Leaders
segment - 07.06.2022
Inventiva (EU:IVA)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Inventiva (EU:IVA)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024